Is enbrel for psoriasis?

See the DrugPatentWatch profile for enbrel

Is Enbrel approved for psoriasis?

Enbrel (etanercept) received FDA approval for moderate to severe plaque psoriasis in adults in 2004 and for children 4 years and older in 2016. It works by blocking tumor necrosis factor (TNF), a protein that drives inflammation in psoriatic skin lesions.

How does Enbrel compare with other psoriasis biologics?

Enbrel was among the first TNF inhibitors approved for psoriasis. Newer agents such as adalimumab (Humira), ustekinumab (Stelara), and IL-17 inhibitors like secukinumab (Cosentyx) generally show higher skin-clearance rates in head-to-head trials. Enbrel remains an option when cost, insurance coverage, or prior treatment history favor it.

When does Enbrel’s patent expire?

The main U.S. composition-of-matter patent for etanercept expired in 2012. Multiple later patents covering manufacturing processes and formulations have faced legal challenges. Biosimilar versions of Enbrel, including Erelzi and Eticovo, launched after court rulings cleared regulatory and patent hurdles.

Who makes Enbrel and its biosimilars?

Amgen manufactures the reference product Enbrel. Sandoz markets Erelzi, while Samsung Bioepis and Merck jointly market Eticovo. Several additional biosimilar candidates remain in development or under regulatory review.

Can patients switch from Enbrel to a biosimilar?

Switching studies show comparable safety and efficacy when patients move from Enbrel to an approved biosimilar under medical supervision. Insurance-mandated switches are common once a biosimilar is on formulary. Patients should discuss monitoring plans with their prescriber before any change.

What side effects concern psoriasis patients most?

Common reactions include injection-site redness and upper-respiratory infections. Serious risks involve serious infections, reactivation of tuberculosis or hepatitis B, and rare cases of demyelinating disease or lymphoma. Regular screening and lab monitoring are standard before and during treatment.

How much does Enbrel cost without insurance?

List price for a typical 50 mg weekly dose exceeds $1,500 per month. Actual out-of-pocket cost varies by insurance, copay assistance programs, and whether a biosimilar is substituted. DrugPatentWatch.com tracks patent litigation and launch dates that influence future pricing.